OncoMatch/Clinical Trials/NCT06659042
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Is NCT06659042 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Cisplatin for lung cancer, non-small cell.
Treatment: Tislelizumab · Cisplatin · Carboplatin · Pemetrexed Disodium — The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS mutation
Disease stage
Required: Stage II, IIIA, IIIB (N2) (AJCC 8th edition)
stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any treatment for the current lung cancer
Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy
Cannot have received: systemic immunomodulatory agents (interferon, interleukin-2, tumor necrosis factor, thymosin α1, thymalfasin)
Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose
Cannot have received: herbal medicine to control cancer
Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug
Cannot have received: live or attenuated live vaccines
Received live or attenuated live vaccines within 4 weeks prior to enrollment or expected to require live or attenuated live vaccines during the study or within 5 months after the last dose of tislelizumab
Lab requirements
Cardiac function
good cardiopulmonary function, meeting the requirements for surgical resection with curative intent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify